History of Dapoxetine and Priligy

February 27, 2018

History of Dapoxetine and Priligy

Home - Blog - History of Dapoxetine and Priligy
Priligy (dapoxetine hydrochloride), also called dapoxetine, is an oral medication for the treatment of premature ejaculation (PE). Dapoxetine was initially developed as an anti-depressant in the form of a selective serotonin reuptake inhibitor (SSRI), similar to Paxil and Zoloft. Dapoxetine didn't work very well as an anti-depressant because of problems with the pharmacokinetics. Basically, the drug absorbs relatively quickly and doesn't stay in the body for days like other SSRIs.

Dapoxetine for Premature Ejaculation

Like other SSRIs, dapoxetine delays orgasm (in women as well as men) and ejaculation. Many physicians prescribe SSRIs for premature ejaculation. However, since these antidepressants are not approved by the FDA for PE, SSRIs must be prescribed off-label. Because dapoxetine was shorter-acting than other SSRIs, Eli Lilly, the developer of dapoxetine, targeted the drug for premature ejaculation with the hope of reduce the side effects of other SSRIs.

How Did Dapoxetine Become Priligy?

In 1998, Eli Lilly sold the right to dapoxetine to PPD GenuPro who intended to develop and market the drug for premature ejaculation. In 2001, PPD sold the worldwide marketing and development rights to ALZA Corporation, which was acquired by Johnson & Johnson about the same time. In 2003, PPD bought the patents for dapoxetine from Eli Lilly. Johnson and Johnson named the product Priligy and began approval and marketing efforts through their various world-wide units, primarily Janssen.

Current Distribution of Priligy

In May of 2012, USA-based Furiex Pharmaceuticals was transferred the worldwide rights for Priligy from ALZA Corp and Janssen Pharmaceutica (both part of the Johnson & Johnson group). At the same time, Furiex entered an agreement with Italian drugmaker Menarini, for rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East. Furiex retains full development and commercialization rights in the USA, Japan and Canada.

Furiex was scheduled to receive $15 million on closing, up to $20 million in regulatory and launch milestones and up to $40 million in sales-based milestones, plus tiered royalties on product sales ranging from mid-teens to mid-twenties in percentage terms. Menarini will assume responsibility for commercialization activities in the licensed territories and will fund on-going clinical trials.

FDA Approval of Dapoxetine / Priligy

Despite approval in other countries, Dapoxetine has not achieved FDA approval for distribution in the United States.

LEAVE A COMMENT

Things You'll love

The Standard

The Standard

$59.95

Lorem Ipsum

Add To Cart

Premium Water Lube

Premium Water Lube

$12.99

Lorem Ipsum

Add To Cart

VitaFLUX

VitaFLUX

$59.95

Lorem Ipsum

Add To Cart

You might also like

The Refractory Period
Feb 22, 2019

The Refractory Period

Songs that croon about “doing it all night long” paint a lovely (if exhausting) picture of glistening, naked ecstasy. But in reality, the male reproductive system just...

Read More    

Getting Back in Bed After Treating Premature Ejaculation
Feb 22, 2019

Getting Back in Bed After...

Treating the physical issues related to premature ejaculation is sometimes only half the issue. Get back into the saddle again with some sage advice.

Read More    

Can Your Diet Fix Premature Ejaculation?
Feb 22, 2019

Can Your Diet Fix Prematu...

Food has a role in all things related to your health, and premature ejaculation is no exception. Learn how much diet impacts your sexual performance.

Read More